Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy

Abstract

Patients treated with S-1 therapy had a better prognosis than patients without S-1. One metastatic site and being given second-line chemotherapy were other factors for better prognosis. For patients with only one metastatic site, a good prognosis can be obtained by second-line chemotherapy for those refractory to S-1. The prognosis of patients who had more than two metastatic sites remained poor; more effective chemotherapy might improve the survival of such patients if they retain good performance status.

Proposal to Subclassify Stage IV Gastric Cancer Into IVA, IVB, and IVM

“…5,[8][9][10] A radical gastrectomy is the treatment for gastric cancer that is most highly associated with cure. However, patients with stage IV gastric cancer often receive other palliative surgical or nonsurgical procedures owing to their advanced disease status.…”

Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line

“…Among anticancer drugs for gastric cancer, S-1, a 5-FU analog, has recently become the standard first-line chemotherapeutic drug in Japan, while several other new drugs, including the topoisomerase I inhibitors CPT-11 and ADR, are less frequently used (13,14). These drugs provide an improved prognosis for advanced gastric cancer (6,15). ROS, including non-radical hydrogen peroxide (H 2 O 2 ), organic hydroperoxide (ROOH), and hypochlorous acid (HClO), are generated from inflammatory immune cells such as activated macrophages and neutrophils, which accumulate at sites of inflammation.…”